Kancera starts study in covid-19 patients

Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that screening of covid-19 patients for the clinical phase II study of KAND567 starts today. The study, which is carried out in collaboration with Capio St. Göran's Hospital and Petter...

Kancera startar idag studie i covid-19 patienter

Kancera AB (Nasdaq First North Premier Growth Market: KAN) meddelar att screening av covid-19-patienter för den kliniska fas II-studien av KAND567 startar idag. Studien som genomförs i samarbete med Capio S:t Görans sjukhus och Petter Brodin’s forskargrupp på...